947144-20-9

Upstream product

• 947144-38-9 4-benzylamino-3-nitro-6-trifluoromethyl-1H-pyridin-2-one 
• 947144-53-8 4-chloro-3-nitro-6-trifluoromethyl-1H-pyridin-2-one 
• 947144-26-5 4-hydroxy-3-nitro-6-trifluoromethyl-1H-pyridin-2-one 
• 947144-28-7 4-hydroxy-2-oxo-6-trifluoromethyl-1,2-dihydropyridine-3-carboxylic acid ethyl ester 
• 947144-18-5 benzyl-(2-chloro-3-nitro-6-trifluoromethylpyridin-4-yl)amine 
• 530-62-1 1,1'-carbonyldiimidazole 

Downstream Products

• 947143-86-4 1-Benzyl-4-benzylamino-6-trifluoromethyl-1,3-dihydro-imidazo[4,5-c]pyridine-2-one 
• 947142-81-6 4-amino-1-benzyl-6-trifluoromethyl-1,3-dihydroimidazo[4,5-c]pyridin-2-one 

Relevant academic research and scientific papers

Development of a practical synthesis of Toll-like receptor agonist PF-4171455: 4-amino-1-benzyl-6-trifluoromethyl-1,3-dihydroimidazo [4,5-c] pyridin-2-one

The development and implementation of a scalable process for the manufacture of the Toll-like receptor (TLR7) agonist PF-4171455 (1) is described. Initial routes used to synthesise 1 in milligram quantities were unsuitable for large-scale synthesis to pro

NOVEL PHARMACEUTICALS

The present invention relates to immune response modifiers of formula (I), which act selectively through agonism, of Toll-Like Receptors (TLRs), uses thereof, processes for the preparation thereof, intermediates used in the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including the treatment of infectious disease such as Hepatitis (e.g. HCV, HBV), genetically related viral infection and cancer.